Patent claims:

1. A filled, sealed and optionally labeled safety container for biologically active substances having an increased or high fracture strength and shatterproof strength, and a contamination-free outer surface, the container having a hollow body having at least one opening, one closure each per opening, optionally a label, and comprising at least one biologically active substance filled into the hollow body, characterized in that a coating has been applied completely or partially to the filled, sealed and optionally labeled container.

2. The safety container as claimed in claim 1, characterized in that it has been provided with a label before or after applying the coating.

3. The safety container as claimed in one of the above claims, characterized in that it has been treated with a wash medium before the attachment of the coating to the filled, sealed and optionally labeled container.

4. The safety container as claimed in one of the above claims, characterized in that the coating takes place at room temperature.

5. The safety container as claimed in one of the above claims, characterized in that the coating has been attached to the container completely or almost completely.

6. The safety container as claimed in one of the above claims, characterized in that the container is manufactured from glass and/or plastic.

7. The safety container as claimed in one of the above claims, characterized in that at least one closure comprises a rubber stopper and a crimped cap.

8. The safety container as claimed in one of the above claims, characterized in that the marking is a marking surface, preferably a written label of paper and/or plastic.

9. The safety container as claimed in one of the above claims, characterized in that the biologically active substance has a liquid, solid or amorphous physical state at room temperature.

10. The safety container as claimed in one of the above claims, characterized in that the biologically active substance is a cytotoxic substance.

11. The safety container as claimed in one of the above claims, characterized in that the cytotoxic substance has been selected from the group consisting of ifosfamide, cyclophosphamide, trofosfamide, mafosfamide, S303, mitoxantrone, LHRH antagonists and glufosfamide.

12. The safety container as claimed in one of the above claims, characterized in that the coating has been attached by means of the steps i) treatment of the filled, sealed and optionally labeled container with a medium which contains at least one polymer, and ii) subsequent drying of the container treated with the medium.

13. The safety container as claimed in one of the above claims, characterized in that the treatment has been carried out by spraying.

14. The safety container as claimed in one of the above claims, characterized in that the spraying has been carried out by the use of shear forces (e.g. use of a nozzle) and/or use of flow forces (e.g. use of a rotating disk).

15. The safety container as claimed in one of the above claims, characterized in that the treatment has been carried out by immersion.

16. The safety container as claimed in one of the above claims, characterized in that the treatment has been carried out by application of a powder.

17. The safety container as claimed in one of the above claims, characterized in that the medium containing at least one polymer

has been selected from the group consisting of powder, dispersion, emulsion, suspension and solution.

18. The safety container as claimed in one of the above claims, characterized in that at least one polymer which is contained in the medium has been selected from the group consisting of polyurethane, polyester and polyester-polyurethane mixtures.

19. A process for the production of filled, sealed and optionally labeled safety containers for biologically active substances having increased or high fracture strength and shatterproof strength, and a contamination-free outer surface, the container comprising a hollow body having at least one opening, one closure each per opening, optionally a label, and at least one biologically active substance filled into the hollow body, and a coating having been applied completely or partially to the outside of the filled, sealed and optionally labeled container, characterized by the steps i) treatment of the filled, sealed and optionally labeled container with a medium which contains at least one polymer, and ii) drying of the container treated with the medium.

20. The process as claimed in one of the above claims, characterized in that the safety container is provided with a label before or after the application of the coating.

21. The process as claimed in one of the above claims, characterized in that before the treatment the filled, sealed and optionally labeled container is treated with a wash medium.

22. The process as claimed in one of the above claims, characterized in that the treatment is carried out at approximately room temperature.

23. The process as claimed in one of the above claims, characterized in that the drying is carried out at approximately room temperature.

24. The process as claimed in one of the above claims, characterized in that the coating has been applied to the container completely or almost completely.

25. The process as claimed in one of the above claims, characterized in that the container has been manufactured from glass and/or plastic.

26. The process as claimed in one of the above claims, characterized in that at least one closure comprises a rubber stopper and a crimped cap.

27. The process as claimed in one of the above claims, characterized in that the marking is a marking surface, preferably a written label of paper and/or plastic.

28. The process as claimed in one of the above claims, characterized in that the biologically active substance has a liquid, solid or amorphous physical state at room temperature.

29. The process as claimed in one of the above claims, characterized in that the biologically active substance is a cytotoxic substance.

30. The process as claimed in one of the above claims, characterized in that the cytotoxic substance has been selected from the group consisting of ifosfamide, cyclophosphamide, trofosfamide, mafosfamide, S303, mitoxantrone, LHRH antagonists and glufosfamide.

31. The process as claimed in one of the above claims, characterized in that the treatment has been carried out by spraying.

32. The process as claimed in one of the above claims, characterized in that the spraying has been carried out by use of shear forces (e.g. use of a nozzle) and/or use of flow forces (e.g. use of a rotating disk).

33. The process as claimed in one of the above claims, characterized in that the treatment has been carried out by immersion.

34. The process as claimed in one of the above claims, characterized in that the treatment has been carried out by application of a powder.

35. The process as claimed in one of the above claims, characterized in that the medium containing at least one polymer has been selected from the group consisting of powder, dispersion, emulsion, suspension and solution.

36. The process as claimed in one of the above claims, characterized in that at least one polymer which is contained in the medium has been selected from the group consisting of polyurethane, polyester and polyester-polyurethane mixtures.

37. A safety container for biologically active substances having an increased or high fracture strength and shatterproof strength, and a contamination-free outer surface, which can be prepared as set forth in the process as claimed in one of the above claims.

38. A safety container for biologically active substances having an increased or high fracture strength and shatterproof strength, and a contamination-free outer surface, prepared as set forth in the process as claimed in one of the above claims.

39. The use of a medium which contains at least one polymer for the treatment of a filled, sealed and optionally labeled container for biologically active substances, the container comprising a hollow body provided with at least one opening, one closure each per opening, a marking and at least one biologically active substance filled into the hollow body and a coating being applied to the outside of the filled, sealed and optionally labeled container by the treatment with the medium.

40. The use of a medium which contains at least one polymer for the decontamination of the outer surface, and increase in the fracture strength and shatterproof strength, of a container for biologically active substances filled with a biologically active substance, sealed and optionally labeled, the container comprising a hollow body provided with at least one opening, one closure each per opening, a marking and at least one biologically active substance filled into the hollow body and the decontamination being carried out by

application of a coating to the outside of the filled, sealed and optionally labeled container.

41. The use as claimed in one of the above claims, characterized in that before the treatment the filled, sealed and optionally labeled container is treated with a wash medium.

42. The use as claimed in one of the above claims, characterized in that the treatment is carried out at approximately room temperature.

43. The use as claimed in one of the above claims, characterized in that the drying is carried out at approximately room temperature.

44. The use as claimed in one of the above claims, characterized in that the coating is applied to the container completely or almost completely.

45. The use as claimed in one of the above claims, characterized in that the container has been manufactured from glass and/or plastic.

46. The use as claimed in one of the above claims, characterized in that at least one closure comprises a rubber stopper and a crimped cap.

47. The use as claimed in one of the above claims, characterized in that the marking is a marking surface, preferably a written label of paper and/or plastic.

48. The use as claimed in one of the above claims, characterized in that the biologically active substance has a liquid, solid or amorphous physical state at room temperature.

49. The use as claimed in one of the above claims, characterized in that the biologically active substance is a cytotoxic substance.

50. The use as claimed in one of the above claims, characterized in that the cytotoxic substance has been selected from the group consisting of ifosfamide, cyclophosphamide, trofosfamide, mafosfamide, S303,

mitoxantrone, LHRH antagonists and glufosfamide.

51. The use as claimed in one of the above claims, characterized in that the treatment has been carried out by spraying.

52. The use as claimed in one of the above claims, characterized in that the spraying has been carried out by use of shear forces (e.g. use of a nozzle) and/or use of flow forces (e.g. use of a rotating disk).

53. The use as claimed in one of the above claims, characterized in that the treatment has been carried out by immersion.

54. The use as claimed in one of the above claims, characterized in that the treatment has been carried out by application of a powder.

55. The use as claimed in one of the above claims, characterized in that the medium containing at least one polymer has been selected from the group consisting of powder, dispersion, emulsion, suspension and solution.

56. The use as claimed in one of the above claims, characterized in that at least one polymer which is contained in the medium has been selected from the group consisting of polyurethane, polyester and polyester-polyurethane mixtures.